This is a preview of subscription content, log in via an institution to check access.
References
Abilleira S., Bevan S. and Markus H. S. 2006 The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet. 43, 897–901.
Alpert J. S., Thygesen K., Antman E. and Bassand J. P. 2000 Myocardial infarction redefined — a consensus document of The Joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J. Am. Coll. Cardiol. 36, 959–969.
Ciruzzi M., Schargrodsky H., Pramparo P., Rivas Estany E., Rodriguez Naude L., de la Noval Garcia R. et al. 2003 Attributable risks for acute myocardial infarction in four countries of Latin America. Medicina (Buenos Aires) 63, 697–703.
Gonzalez-Hernandez N. A., Millan-Guerrero R. O., Ceja-Espiritu G., Baltazar-Rodriguez L. M., Rodriguez-Salazar R., Olmedo-Buenrostro B. A. et al. 2008 A polymorphism in the matrix metalloproteinase-2 (MMP-2 — 1306T>C) gene promoter is associated with high risk of ischemic stroke in hypertensive patients. Genes Genom. 30, 533–540.
Hlatky M. A., Ashley E., Quertermous T., Boothroyd D. B., Ridker P., Southwick A. et al. 2007 Atherosclerotic disease, vascular function and genetic epidemiology (ADVANCE) study. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J. 154, 1043–1051.
Hojo Y., Ikeda U., Ueno S., Arakawa H. and Shimada K. 2001 Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn. Circ. J. 65, 71–75.
Horne B. D., Camp N. J., Carlquist J. F., Muhlestein J. B., Kolek M. J., Nicholas Z. P. and Anderson J. L. 2007 Multiplepolymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J. 154, 751–758.
Hsieh K., Lalouschek W., Schillinger M., Endler G., Reisinger M., Janisiw M. et al. 2005 Impact of ENaC Polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study. Clin. Chem. 51, 952–956.
Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F. et al. 1998 Peripheral blood levels of matrix metalloproteases-2 and −9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32, 368–372.
Medina-Mora M. A., Peña-Corona M. P., Cravioto P., Villatoro J. and Kuri P. 2002 Del tabaco al uso de otras drogas: ?el uso temprano de tabaco aumenta la probabilidad de usar otras drogas? Salud Publica Mex. 44, S109–S115.
Newby A. C. 2005 Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85, 1–31.
Park H. Y., Kwon H. M., Lim H. J., Hong B. K., Lee J. Y., Park B. E. et al. 2001 Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp. Mol. Med. 33, 95–102.
Pasterkamp G., Schoneveld A. H., Hijnen D. J., de Kleijn D. P., Teepen H., van der Wal A. C. and Borst C. 2000 Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 150, 245–253.
Peterson J. T. 2006 The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677–687.
Price S. J., Greaves D. R. and Watkins H. 2001 Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J. Biol. Chem. 276, 7549–7558.
Suzuki H., Kusuyama T., Sato R., Yokota Y., Tsunoda F., Sato T. et al. 2008 Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. Eur. J. Clin. Invest. 38, 166–173.
Tedgui A. and Mallat Z. 2006 Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86, 515–581.
Vasku A., Goldbergová M., Izakovicová Holla L., Sisková L., Groch L., Beránek M. et al. 2004 A haplotype constituted of four MMP-2 promoter polymorphisms (− 1575G/A, −1306C/T, −790T/G and −735C/T) is associated with coronary triple-vessel disease. Matrix Biol. 22, 585–591.
Yasmin, McEniery C. M., Wallace S., Dakham Z., Pulsalkar P., Maki-Petaja K. et al. 2005 Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 25, 372–378.
Zhou H. Z., Ma X., Gray M. O., Zhu B. Q., Nguyen A. P., Baker A. J., Simonis U. et al. 2007 Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem. Biophys. Res. Commun. 358, 189–195.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Delgado-Enciso, I., Gonzalez-Hernandez, N.A., Baltazar-Rodriguez, L.M. et al. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J Genet 88, 249–252 (2009). https://doi.org/10.1007/s12041-009-0035-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12041-009-0035-9